Forest Enters Antibiotic Field Through Faropenem Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest will oversee U.S. sales and marketing efforts for the pending antibiotic Orapem under an agreement with Replidyne.
You may also be interested in...
Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.
Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.
Lexapro Scripts Hold Up Against Competition From Generic Zoloft
Forest's antidepressant shows prescription growth in September, despite August entry of generic Zoloft.